Grant Funded Startups in Switzerland
Grant-funded rounds in Switzerland (27 rows) show a steep size gap: the largest disclosed amount is Limula’s $5M grant on 2022-06-15, which dwarfs the next…
Grant-funded rounds in Switzerland (27 rows) show a steep size gap: the largest disclosed amount is Limula’s $5M grant on 2022-06-15, which dwarfs the next-largest disclosed rounds of $2M (PeriVision on 2021-12-21; ExoLabs on 2021-08-16) and $8M (Kinarus Therapeutics on 2021-12-13) is actually larger than $5M, so the true largest is Kinarus Therapeutics’ $8M on 2021-12-13; all other disclosed amounts cluster far below that level. Date-wise, entries are concentrated in a late-2022 window, with multiple grants closing on 2022-10-21 (Evolva $540K; Ocumeda $150K) and 2022-06-07 (Flowbone $820K; Topadur Pharma $620K), while earlier 2021 entries taper off across December (GeNeuro $7M on 2021-12-13; Memo Therapeutics $11M on 2021-12-13) and then spread through September–August. Sector clustering is dominated by Biotechnology: 9 of 27 companies list Biotechnology, alongside smaller groupings in AI, Health Care, and Information Technology. Geographic patterns skew toward Zurich-area entries, including multiple Zürich, Zürich rows (e.g., Correntics 2022-10-07 $150K; Versantis 2022-04-13 $500K; BioLingus is in Hergiswil) rather than a single city monopoly. Two entries use undisclosed amounts (BioLingus on 2022-09-08; Groam on 2022-06-16), which creates gaps in size-based comparisons. The most recent round date shown is 2022-10-21 (Evolva and Ocumeda), and the oldest is 2021-07-01 (Raized.ai).
Most recent rounds
27 shownRelated listings
Frequently asked
What is the largest disclosed grant in this Switzerland list, and how does it compare to the rest of the disclosed amounts?
Memo Therapeutics’ $11M grant on 2021-12-13 is the highest disclosed amount in the table. The next-largest disclosed rounds are $8M (Kinarus Therapeutics on 2021-12-13) and $7M (GeNeuro on 2021-12-13), after which most other disclosed grants sit well below the $2M–$3M range (e.g., $820K Flowbone on 2022-06-07; $620K Topadur Pharma on 2022-06-07).
Do any dates form a tight cluster where multiple grants close around the same time?
Yes. The list shows multiple same-day closings in 2022: 2022-10-21 includes Evolva ($540K) and Ocumeda ($150K), and 2022-06-07 includes Flowbone ($820K) and Topadur Pharma ($620K). A second density point appears on 2021-12-13, where GeNeuro ($7M), Kinarus Therapeutics ($8M), and Memo Therapeutics ($11M) all share the same date.
Are there sectors that appear disproportionately often across these 27 rows?
Biotechnology is the clear concentration: 9 of 27 companies list Biotechnology (e.g., Evolva 2022-10-21 $540K; Limula 2022-06-15 $5M; GeNeuro 2021-12-13 $7M). Other sectors appear fewer times, such as AI (SightIn Health 2022-08-25 $160K; PeriVision 2021-12-21 $2M; DeepJudge 2021-12-14 $200K; Raized.ai 2021-07-01 $300K).
Which city appears most often, and is it mainly driven by Zurich?
Zürich-region entries are over-represented, with repeated “Zürich, Zurich, Switzerland” rows such as Correntics (2022-10-07 $150K), Versantis (2022-04-13 $500K), and DeepJudge (2021-12-14 $200K). The table is not exclusively Zurich—there are entries in Geneva (SightIn Health 2022-08-25; Exomotion 2021-09-24) and Vaud (Composite Recycling 2022-07-04; Tune Insight 2022-02-24), but the concentration around Zürich is consistent across multiple dates.
Which entries are the outliers by disclosed amount, smallest disclosed, or missing amounts?
The largest disclosed outlier is Memo Therapeutics at $11M (2021-12-13), followed by Kinarus Therapeutics at $8M (same date) and GeNeuro at $7M (2021-12-13). The smallest disclosed amount is TissueLabs at $100K (2021-09-12). Two rows are missing disclosed amounts—BioLingus (undisclosed on 2022-09-08) and Groam (undisclosed on 2022-06-16)—so any comparisons against the low end cannot fully include those entries.
What does the stage mix look like in this page, and are there any rounding-time gaps due to undisclosed amounts?
Stage is consistently labeled as “Grant” across all 27 rows in the table, so the mix is not stage-driven. However, two grants use “undisclosed” amounts (BioLingus on 2022-09-08 and Groam on 2022-06-16), creating gaps specifically for size-based analysis rather than for stage classification.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.